June 15, 2020 / 12:14 PM / a month ago

BRIEF-Catalyst Presents Positive Final Data From Phase 2B Trial Of Subcutaneous Dalcinonacog Alfa

June 15 (Reuters) - Catalyst Biosciences Inc:

* CATALYST BIOSCIENCES PRESENTS POSITIVE FINAL DATA FROM ITS PHASE 2B TRIAL OF SUBCUTANEOUS DALCINONACOG ALFA (DALCA) AT THE WORLD FEDERATION OF HEMOPHILIA VIRTUAL SUMMIT 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below